27.77
0.63 (2.32%)
| Previous Close | 27.14 |
| Open | 27.33 |
| Volume | 271,999 |
| Avg. Volume (3M) | 318,805 |
| Market Cap | 1,288,172,544 |
| Price / Earnings (Forward) | 250.00 |
| Price / Sales | 12.79 |
| Price / Book | 3.07 |
| 52 Weeks Range | |
| Earnings Date | 26 Feb 2025 - 3 Mar 2025 |
| Profit Margin | -24.54% |
| Operating Margin (TTM) | -40.48% |
| Diluted EPS (TTM) | -0.250 |
| Quarterly Revenue Growth (YOY) | 29.70% |
| Total Debt/Equity (MRQ) | 8.65% |
| Current Ratio (MRQ) | 4.55 |
| Operating Cash Flow (TTM) | 8.43 M |
| Levered Free Cash Flow (TTM) | 43.83 M |
| Return on Assets (TTM) | -1.10% |
| Return on Equity (TTM) | -3.32% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Mixed |
| Medical Instruments & Supplies (Global) | Bearish | Mixed | |
| Stock | BioLife Solutions, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -3.5 |
| Average | -0.13 |
|
BioLife Solutions Inc is active in the healthcare segment. The company is engaged in developing, manufacturing, and marketing a portfolio of biopreservation tools and services for cells, tissues, and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud, hosted biologistics cold chain management application for shippers. The company's product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Core |
| % Held by Insiders | 2.47% |
| % Held by Institutions | 101.86% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 31.00 (Northland Capital Markets, 11.63%) | Buy |
| Median | 30.50 (9.83%) | |
| Low | 30.00 (HC Wainwright & Co., 8.03%) | Buy |
| Average | 30.50 (9.83%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 27.25 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 06 Mar 2025 | 30.00 (8.03%) | Buy | 26.80 |
| Northland Capital Markets | 08 Jan 2025 | 31.00 (11.63%) | Buy | 27.69 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 18 Mar 2025 | Announcement | BioLife Solutions Appoints Cathy Coste as Director and Audit Committee Chair |
| 03 Mar 2025 | Announcement | BioLife Solutions Reports Fourth Quarter and Full Year 2024 Financial Results |
| 20 Feb 2025 | Announcement | BioLife Solutions to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on March 3, 2025 |
| 13 Jan 2025 | Announcement | BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2024 Unaudited Revenue from Continuing Operations |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |